Beyondspring Inc 's

Name: Beyondspring Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BYSI Sales vs. its Competitors Q2 2026

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

<< BYSI Stock Performance Comparisons

Beyondspring Inc 's Comment on Competition and Industry Peers

The company operates in a competitive environment alongside pharmaceutical and biotechnology firms developing cancer treatments, including those employing similar scientific methods and alternative approaches such as molecular glue technology to target oncogene proteins. Competitors encompass academic institutions, government agencies, and various public and private research organizations engaged in research, patent protection, and collaborative drug development and commercialization efforts. The company competes to recruit and retain marketing and sales personnel and to form partnerships with third-party pharmaceutical companies for commercialization. Competitors may develop and obtain regulatory approval for drugs that are safer, more effective, or more convenient, potentially securing a strong market position prior to the company's market entry.

<< See the full list of BYSI competitors

*Market share is calculated based on total revenue.

News about Beyondspring Inc Contracts

Innovative Partnership SEED Therapeutics and Eisai Join Forces to Elevate Therapeutics for Neurodegeneration an...

August 6, 2024
In a significant advancement in the realm of drug discovery, SEED Therapeutics, a pioneering biotechnology company, has announced a strategic research collaboration with Eisai Co., Ltd. This collaboration is aimed at discovering and developing novel molecular glue degraders for treating neurodegenerative diseases and various oncology indications. Concurrently, SEED has secured financing through a Series A-3 agreement led by Eisai, marking a pivotal moment for both entities in their mission to tackle some of the most pressing health challenges of our time. The pharmaceutical industry is witnessing a paradigm shift as researchers explore innovative therapeutic modalities, particularly to address disorder...

BYSI's Stock Performance relative to its Competitors

Publicly Traded Peers of Beyondspring Inc

Sources: Beyondspring Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Beyondspring Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.